Welcome Back |Sign in | Register
Your Position: Home > Inhibitors/Agonists > ML192

View History

ML192
prev zoom next

Name:ML192

  • Catalog No.:
  • BCM006473
  • Chem Name:
  • furan-2-yl(4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methanone
  • Synonym:
  • ML192; ML 192; ML-192; CID1434953; CID-1434953; CID 1434953; MLS000526305
  • CAS No.:
  • 460331-61-7
  • MDL No.:
  • MFCD03127624
  • Formula:
  • C20H22N4O2S
  • Molecular:
  • 382.47928
  • Form:
  • Solid powder
  • Wish  | Compare  | Referral bonuses
SKU Specification Brand Prices Stock Quantity Cart
BCM006473-10MG 10mg, Purity:98% BCM $366 0 Add Cart
BCM006473-25MG 25mg, Purity:98% BCM $445 0 Add Cart
BCM006473-50MG 50mg, Purity:98% BCM $745 0 Add Cart
For more quantities, please contact telephone:0755-85269922,Or send an email to:sales@biochemmall.com

Product Description

Attribute

Goods Tag

Related Products

 

ML192, also known as MLS000526305 and CID1434953, is a selective ligands for GPR55. The orphan G protein coupled receptor, ML192 (CID1434953) with 1080 nM potency for GPR55 and >45-fold antagonist and agonist selectivity against GPR35, CB1 and CB2. GPR55 has gained notoriety because of its putative identification as a cannabinoid receptor subtype. The significance of this assignment should not be underestimated given the importance of cannabinoids to drug abuse and the potential utility of cannabinoid ligands in treating behavioral disorders leading to conditions such as obesity.

 

Brand: BCM

 

Solubility: Soluble in DMSO, not in water

 

InChi Key: GDPDARVUXXOYAJ-UHFFFAOYSA-N

 

Attribute
[Chem Name] furan-2-yl(4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methanone
[Synonym] ML192; ML 192; ML-192; CID1434953; CID-1434953; CID 1434953; MLS000526305
[CAS No.] 460331-61-7
[MDL No.] MFCD03127624
[Formula] C20H22N4O2S
[Molecular] 382.47928
[Form] Solid powder

Goods Tag

User Comment(Total0User Comment Num)

  • No comment
Total 0 records, divided into1 pages. First Prev Next Last
Username: Anonymous user
E-mail:
Rank:
Content:
Verification code: captcha